OrderlyMeds has announced a tiered pricing structure for compounded semaglutide and tirzepatide, offering all-inclusive plans starting at $149/month for individuals seeking weight management support without insurance coverage.
-- A new tiered pricing model for compounded GLP-1 medications — including semaglutide and tirzepatide — is now available through OrderlyMeds, giving uninsured patients a clearer picture of what treatment will cost before they commit. The structure includes an introductory multi-month program for new patients, followed by a flat ongoing monthly rate.
More information is available at https://orderlymeds.com/pricing/
The announcement comes amid shifting regulatory conditions affecting compounded GLP-1 medications. In February 2026, the U.S. Food and Drug Administration (FDA) indicated plans to restrict certain active pharmaceutical ingredients used in unapproved compounded GLP-1 drugs. The development has increased focus on transparency and patient awareness when considering compounded treatment options, including how pricing is communicated to prospective patients.
Under OrderlyMeds' new structure, compounded semaglutide is offered through a three-month starter program priced at $224, followed by a monthly rate of $149. Compounded tirzepatide is available at $449 for an initial three-month period, with subsequent monthly pricing set at $299. The company states that these fees are all-inclusive, covering provider consultations, prescribed medication, necessary supplies, shipping, and ongoing support. Additionally, OrderlyMeds includes over $3,700 in additional resources at no extra cost, such as dietitian-created meal plans, fitness app subscriptions, and expert-led webinars, differentiating the platform from competitors focused solely on prescription fulfillment.
OrderlyMeds says the pricing structure is intended to provide clarity around total treatment costs, particularly for uninsured or underinsured individuals who may face barriers to accessing brand-name alternatives. The company works with state-licensed 503A compounding pharmacies in the United States, where medications are prepared based on individualized prescriptions and are subject to state regulatory oversight. Compounded formulations are prescribed only when a licensed healthcare provider determines that a customized preparation is appropriate for a patient's specific clinical needs.
OrderlyMeds states that patients using the platform have reported measurable weight loss outcomes over structured treatment periods, with individualized care and clinical oversight central to the company's approach.
OrderlyMeds says the updated structure responds to growing demand for clearly defined, accessible treatment options in the weight management sector, particularly as regulatory scrutiny of compounded medications continues to evolve.
For more information and to check eligibility, visit https://orderlymeds.com/
Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/
Source: PressCable
Release ID: 89189177
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.